Angiogenesis research: Guidelines for translation to clinical application

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 23-33

  Folkman, J ^a   Browder, T ^a   Palmblad, J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Angiogenesis inhibitor; Antiangiogenic therapy; Leukemia

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; CHLOROQUINE; CILENGITIDE; COLLAGENASE 3; COMBRETASTATIN; DOXORUBICIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; MARIMASTAT; MEPACRINE; MONOCLONAL ANTIBODY LM 609; PENTOXIFYLLINE; PRINOMASTAT; REBIMASTAT; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 12; SQUALAMINE; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE MARKER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG TARGETING; ENDOTHELIUM CELL; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEMATOLOGIC DISEASE; HEMATOPOIETIC SYSTEM; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MICROVASCULATURE; MULTIDRUG RESISTANCE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; RISK ASSESSMENT; SOLID TUMOR; TREATMENT PLANNING;

EID: 0034924216     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616197     Document Type: Conference Paper

References (102)

1. Tumor angiogenesis: Therapeutic implications
2. Antiangiogenesis: New concept for therapy of solid tumors
3. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
4. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
5. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
6. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis
7. Tumor angiogenesis
8. Angiogenesis
9. Angiogenesis. From the molecular to integrative pharmacology
10. Cancer looking outside the genome
11. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
12. Inhibition of tumor angiogenesis as a strategy to circumvent resistance to anticancer therapeutic agents
13. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
14. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis
15. Complete regression of metastatic cervical cancer with the angiogenesis inhibitor TNP-470
16. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
17. Antiangiogenic therapy of haemangiomas with interferon A
18. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas
19. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site
20. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
21. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
22. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
23. Tumor angiogenesis: The role of oncogenes and tumor suppressor genes
24. E-selectin is upregulated in proliferating endothelial cells in vitro
25. Soluble E-selectin and its ligand sialyl-Lea in human colorectal cancer
26. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
27. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer
28. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
29. Dose-dense therapy with weekly 1-hour paclitaxel infusions in treatment of metastatic breast cancer
30. Salvage weekly paclitaxel in recurrent ovarian cancer
31. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: Results of a phase I/II trial
32. Treatment of non-small-cell lung cancer with prolonged oral etoposide
33. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide
34. Daily oral etoposide in metastatic breast cancer
35. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
36. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
37. The microtubule-affecting drug paclitaxel has antiangiogenic activity
38. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
39. Regulation of angiogenesis
40. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
41. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
42. Bone marrow angiogenesis and progression in multiple myeloma
43. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
44. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
45. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
46. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies
47. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
48. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
49. Prognostic value of bone marrow angiogenesis in multiple myeloma
50. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
51. Abstract volume of the 42nd Annual Meeting of the American Society of Hematology
52. Vascular density, intracellular VEGF and bFGF positivity as prognostic factors in polycythemia vera and chronic myelocytic leukemia
53. Combination angiostatin and endostatin gene transfer induces synergistic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice
54. Thalidomide is an inhibitor of angiogenesis
55. Antitumor activity of thalidomide in refractory multiple myeloma
56. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
57. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
58. Thalidomide in the treatment of relapsed multiple myeloma
59. Successful treatment of multiple myeloma as a single agent
60. Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM)
61. Low-dose thalidomide in the treatment of refractory myeloma
62. Antiangiogenic antitumor activities of cyclooxygenase-2 inhibitors
63. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo
64. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
65. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
66. Thalidomide - A revival story
67. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
68. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
69. Prognostic significance of tumor vascularity
70. The hemostatic system as a regulator of angiogenesis
71. Platelet: Transporter of vascular endothelial growth factor
72. Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis
73. 2-antiplasmin from human platelets
74. 1-antitrypsin
75. The role of the pericellular fibrinolytic system in angiogenesis
76. Inhibition of angiogenesis by peptides derived from kininogen
77. Human prothrombin fragment 1 and 2 inhibit bFGF-induced BCE cell growth
78. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
79. Angiostatin induces and sustains dormancy of human primary tumors in mice
80. Kringle domains of angiostatin: Characterization of the anti-proliferative activity on endothelial cells
81. Role of the light chain of high molecular weight kininogen in adhesion, cell-associated proteolysis and angiogenesis
82. Bone marrow origin of endothelial cell progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
83. Isolation of putative progenitor endothelial cells for angiogenesis
84. Evidence for circulating bone marrow-derived endothelial cells
85. A common precursor for hematopoietic and endothelial cells
86. Isolation and characterization of endothelial progenitor cells from mouse embryos
87. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization
88. Angiogenesis and vasculogenesis as therapeutic strategies for post-natal neovascularization
89. Endothelial progenitor cells as putative targets for angiostatin
90. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function
91. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
92. Establishing a link between oncogenes and tumor angiogenesis
93. Oncogenes and angiogenesis: Signaling three-dimensional tumor growth
94. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
95. Blockade of PDGF-R signaling by STI571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice
96. Can mosaic tumor vessels facilitate molecular diagnosis of cancer?
97. The logic of antiangiogenic gene therapy